original ) (raw )Pseudoprogression in patients with glioblastoma: added value of arterial spin labeling to dynamic susceptibility contrast perfusion MR imaging
Sang Kim , Geon-ho Jahng
Acta radiologica (Stockholm, Sweden : 1987), 2013
View PDFchevron_right
Differentiation between progression and pseudoprogression by arterial spin labeling MRI in patients with glioblastoma multiforme
Ruzica Maksimovic
Journal of B.U.ON. : official journal of the Balkan Union of Oncology, 2017
View PDFchevron_right
Comparative Evaluation of 3-Dimensional Pseudocontinuous Arterial Spin Labeling With Dynamic Contrast-Enhanced Perfusion Magnetic Resonance Imaging in Grading of Human Glioma
Amit Bindal
Journal of Computer Assisted Tomography, 2013
View PDFchevron_right
Assesment of perfusion in glial tumors with arterial spin labeling; comparison with dynamic susceptibility contrast method
Ahmet Bekar
European Journal of Radiology, 2014
View PDFchevron_right
Arterial spin labeling in the grading of brain gliomas: could it help?
doaa emara
Egyptian Journal of Radiology and Nuclear Medicine, 2020
View PDFchevron_right
Perfusion MRI of brain tumours: a comparative study of pseudo-continuous arterial spin labelling and dynamic susceptibility contrast imaging
Carsten W Simonsen
Neuroradiology, 2010
View PDFchevron_right
A Comparative Study of Perfusion Measurement in Brain Tumours at 3 Tesla MR: Arterial Spin Labeling versus Dynamic Susceptibility Contrast-Enhanced MRI
Giovanni Marco
European Neurology, 2010
View PDFchevron_right
Early Evaluation of Tumoral Response to Antiangiogenic Therapy by Arterial Spin Labeling Perfusion Magnetic Resonance Imaging and Susceptibility Weighted Imaging in a Patient With Recurrent Glioblastoma Receiving Bevacizumab
Olivier Chinot
Journal of Clinical Oncology, 2011
View PDFchevron_right
Arterial Spin-Labeling Perfusion MRI Stratifies Progression-Free Survival and Correlates with Epidermal Growth Factor Receptor Status in Glioblastoma
Noriko Salamon
View PDFchevron_right
Glioblastoma: A Method for Predicting Response to Antiangiogenic Chemotherapy by Using MR Perfusion Imaging—Pilot Study 1
Wanyong Shin
Radiology, 2010
View PDFchevron_right
Brain tumor perfusion: Comparison of dynamic contrast enhanced magnetic resonance imaging using T1, T2, and contrast, pulsed arterial spin labeling, and H215O positron emission tomography
Peter Wust
European Journal of Radiology, 2009
View PDFchevron_right
Brain tumor perfusion: Comparison of dynamic contrast enhanced magnetic resonance imaging using T 1, T 2, and T 2 * contrast, pulsed arterial spin labeling, and H 2 15O positron emission tomography
Peter Wust
Eur J Radiol, 2009
View PDFchevron_right
Prognostic value of blood flow measurements using arterial spin labeling in gliomas
J. Schittenhelm , Ulrike Ernemann
PloS one, 2014
View PDFchevron_right
The Use of MR Perfusion Imaging in the Evaluation of Tumor Progression in Gliomas
Ashish Shah
Journal of Korean Neurosurgical Society, 2017
View PDFchevron_right
Facing contrast-enhancing gliomas: perfusion MRI in grade III and grade IV gliomas according to tumor area
Mauro Ceroni , Stefano Bastianello
BioMed research international, 2014
View PDFchevron_right
Arterial spin labeling perfusion: Prospective MR imaging in differentiating neoplastic from non-neoplastic intra-axial brain lesions
Prabhaker Mishra
The neuroradiology journal, 2018
View PDFchevron_right
Repeatability of Cerebral Perfusion Using Dynamic Susceptibility Contrast MRI in Glioblastoma Patients
Jayashree Kalpathy-cramer , Kourosh Jafari-khouzani
Translational Oncology, 2015
View PDFchevron_right
Prospective glioma grading using single-dose dynamic contrast-enhanced perfusion MRI
Sandeep Vaishya
Clinical Radiology, 2015
View PDFchevron_right
Perfusion Magnetic Resonance Imaging Predicts Patient Outcome as an Adjunct to Histopathology: A Second Reference Standard in the Surgical and Nonsurgical Treatment of Low-grade Gliomas
John Golfinos
Neurosurgery, 2006
View PDFchevron_right
Identification of a candidate biomarker from perfusion MRI to anticipate glioblastoma progression after chemoradiation
Danielle Ibarrola
European Radiology, 2016
View PDFchevron_right
Longitudinal DSC-MRI for Distinguishing Tumor Recurrence From Pseudoprogression in Patients With a High-grade Glioma
Benjamin Ellingson
American Journal of Clinical Oncology, 2017
View PDFchevron_right
MRI perfusion in determining pseudoprogression in patients with glioblastoma
Kathryn Beal
Clinical Imaging, 2013
View PDFchevron_right
Early changes in perfusion of glioblastoma during radio- and chemotherapy evaluated by T1-dynamic contrast enhanced magnetic resonance imaging
Svend Engelholm
Acta Oncologica, 2015
View PDFchevron_right
Reevaluating the imaging definition of tumor progression: perfusion MRI quantifies recurrent glioblastoma tumor fraction, pseudoprogression, and radiation necrosis to predict survival
Joseph Heiserman
Neuro-oncology, 2012
View PDFchevron_right
Relative Cerebral Blood Volume Values to Differentiate High-Grade Glioma Recurrence from Posttreatment Radiation Effect: Direct Correlation between Image-Guided Tissue Histopathology and Localized Dynamic Susceptibility-Weighted Contrast-Enhanced Perfusion MR Imaging Measurements
Kris Smith
American Journal of Neuroradiology, 2009
View PDFchevron_right
MRI Parameters and Their Impact on the Survival of Patients with Glioblastoma: Tumor Perfusion Predicts Survival
Ogaga Urhie
World Neurosurgery, 2018
View PDFchevron_right
Diagnostic accuracy and interobserver variability of pulsed arterial spin labeling for glioma grading
Erik David
Acta Radiologica, 2008
View PDFchevron_right
Diagnostic efficacy of perfusion magnetic resonance imaging in supratentorial glioma grading
nafiseh ghavami
Iranian Journal of Radiology, 2018
View PDFchevron_right
Prognostic value of preoperative dynamic contrast-enhanced MRI perfusion parameters for high-grade glioma patients
Vasileios K. Katsaros
Neuroradiology, 2016
View PDFchevron_right
Magnetic resonance spectroscopy as an early indicator of response to anti-angiogenic therapy in patients with recurrent glioblastoma: RTOG 0625/ACRIN 6677
E. Ratai
Neuro-Oncology, 2013
View PDFchevron_right